Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Other

Poisoning

Solute carrier family 22 organic cation transporter member 2 (SLC22A2; OCT2)

Mouse and cell culture studies suggest inhibiting OCT2 could help decrease oxaliplatin-induced neurotoxicity. In a human cell line, a small molecule OCT2 inhibitor decreased oxaliplatin uptake compared with no treatment. In mice receiving oxaliplatin, Oct2 knockout lowered marker expression for oxaliplatin-induced neuropathy compared with no knockout. Next steps include evaluating the ability of OCT2-specific inhibitors in modulating oxaliplatin-induced neuropathy in patients with neurotoxicity.
Oxaliplatin is a generic chemotherapeutic.

SciBX 6(28); doi:10.1038/scibx.2013.735
Published online July 25, 2013

Unpatented; licensing status not applicable

Sprowl, J.A. et al. Proc. Natl. Acad. Sci. USA; published online June 17, 2013;
doi:10.1073/pnas.1305321110
Contact: Alex Sparreboom, St. Jude Children's Research Hospital, Memphis, Tenn.
e-mail:
alex.sparreboom@stjude.org